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Abstract: Due to the great therapeutic interest that involves the translation of mesenchymal stromal
cells (MSCs) into clinical practice, they have been widely studied as innovative drugs, in order to treat
multiple pathologies. MSC-based cell therapy involves the administration of MSCs either locally or
systemically into the receptor body where they can traffic and migrate towards the affected tissue
and participate in the process of healing. The therapeutic effects of MSCs compromise of different
mechanisms such as the functional integration of differentiated MSCs into diseased host tissue after
transplantation, their paracrine support, and their impact on the regulation of both the innate and
the acquired immune system. Here, we establish and provide recent advances about the principal
mechanisms of action through which MSCs can perform their activity and effect as a therapeutic tool.
The purpose of this review is to examine and discuss the MSCs capacity of migration, their paracrine
effect, as well as MSC-mediated modifications on immune cell responses.
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1. Introduction
Mesenchymal stromal cells (MSCs) are multipotent cells which are recognized for being
a subset of non-hematopoietic adult stem cells originating from the mesoderm layer, with
fibroblast-like morphology and multipotent potential [1,2]. MSCs are capable of differentiating
into mesodermal lineages, such as adipocytes, osteocytes, or chondrocytes, and also into endodermic
and neuroectodermic lineages, such as alveolar endothelial cells or neurons [3–5].
Moreover, they are self-renewable and culturally expandable in vitro with few ethical issues,
marking their importance in cell therapy and tissue repairment. MSCs were first isolated from bone
marrow by Friedenstein et al. in the 1960–1970s [6,7]. However, presently it is known that MSCs exist
in almost all tissues. They have been isolated from various human sources, such as the umbilical
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cord, umbilical cord blood, adipose tissue, amniotic fluid, peripheral blood, muscle, and many organs
including fetal liver, brain, lung and so on [4,8].
Although MSCs were successfully derived from all of these tissues, there are practical limitations
such as the difficulty and invasiveness of the procurement [9]. Moreover, MSCs from different tissues
exhibit varied in vitro characteristics, including their proliferation capacity and differentiation potential,
which influence their applicability [10–15]. Therefore, selection of an adequate cell source for their
clinical use should ideally be based on their logistical, practical, and functional behavior [10]. Table 1
describes the advantages and disadvantages of MSCs from the three main sources that have been
investigated in clinical studies: bone marrow, adipose tissue, and the umbilical cord [2] (Table 1).
In order to clarify and harmonize what the fundamental charactericts of MSCs are, the International
Society for Cellular Therapy (ISCT) proposed three minimal criteria for cultured human MSCs definition:
(i) MSCs must be plastic-adherent; (ii) MSCs must have trilineage differentiation potential in vitro
into osteoblasts, adipocytes, and chondroblasts; and (iii) MSCs must be positive (>95%) and negative
(<2%) for a panel of cell surface antigens. Human MSC marker expression must include positive
markers, such as CD105, CD73, and CD90, and negative markers such as CD34, CD45, CD79 or
CD19, CD14 or D11b, and HLA-DR [16]. However, the panel of MSC markers is growing rapidly
and promising markers—which could reach a better MSC identification and enrichment of the stem
cell population—such as CD271 (low affinity nerve growth factor Receptor [LNGFR]), stage-specific
embryonic antigen 4 (SSEA-4), or stromal cell antigen 1 (Stro-1) have been proposed [8].
MSCs can migrate to the accurate place of injury [17], where they can differentiate and replace
damaged resident cells and promote tissue regeneration, as demonstrated in preclinical models of
heart [18], pancreas [19], kidney [20], and liver [21]. However, MSCs not only provide healing
capacities performed through engraftment and differentiation, but also through paracrine signaling
and communication through cell-cell contact. These cells are capable of secreting soluble factors, which
are indispensable for cell viability and proliferation, and for modulating the immune response.
MSC-based cell therapy involves the administration of MSCs into the receptor body, migrating
(or ‘’homing”) towards the affected tissue, and causing direct and indirect modifications over the
immune system and microenvironments acting as a therapeutic agent [22]. MSCs migrate to the injury
site, in response to chemotactic signals released in response of tissue damage [23]. Moreover, the
effects of MSCs are partly based on their capacity to immunomodulate their environment. They are
involved in immunoregulation by interacting with both myeloid and lymphoid cells of innate and
adaptive immune systems, making no-immune activation [24,25]. Among the therapeutic possibilities
of MSC-immune interactions, evidence greatly supports a remarkable effect as immunomodulators
through the secretion of soluble factors and the release of extracellular vesicles (EVs) [26].
Due to the great therapeutic interest involving the clinical translation of MSCs, they are being
widely studied to determine their mechanism of action (MoA) in order to evaluate their efficacy,
feasibility, and safety in humans to treatment of numeorus pathologies [27]. Based on their capacity
to treat or improve the function of a damaged tissue or organs in patients, MSCs are considerated
medicines from the regulatory point of view [28]. Thus, according to each jurisdiction the MSC-based
products are regulated under a specific regulatory framework. In Europe, the European Medicine
Agency classifies human MSCs-based products as Advanced Therapies Medicinal Products (ATMPs).
The ATMPs are regulated under the Regulation No. 1394/2007. On the other hand, in United States of
America, human MSCs are classified by the Food and Drug Administration (FDA) as Human Cellular
and Tissue-based Products (HCT/Ps), and are regulated as a biologic drug under Code of Federal
Regulations, part 1271(21 CFR 1271) [29].
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Table 1. Advantages and disadvantages of mesenchymal stromal cells (MSCs) from the three main sources that have been investigated in clinical studies: bone
marrow (BM), adipose tissue (AT), and the umbilical cord (UC).
Source Type Advantages Disadvantages
Adipose Tissue (AT)  High availability and accessible.
 Stem cell isolation of up to 500 times more than BM.
 Cells proliferate faster than BM-MSCs (mean doubling time of 40 h).
 The immunosuppressive effects of AT-MSCs are stronger than those
of BM-MSCs.
 Secretion of several angiogenic and antiapoptotic cytokines.
 AT-MSCs are more prone to differentiate towards adipocyte lineage.
 Inferior osteogenic and chondrogenic potential in
comparison to BM-MSCs.
 Cell yield and differentiation potential is dependent on
donor characteristics (i.e., age).
Bone Marrow (BM)  The most extensively investigated. Considered to be the
gold standard.
 The most common cellular source in clinical trials. Established
clinical history.
 High chondrogenic and osteogenic potential.
 Invasive and painful collection procedure.
 Procurement carries the risk of infection.
 Limited supply.
 Cell yield and differentiation potential is dependent on
donor characteristics (i.e., age).
 Less proliferative rate in comparison to BM-MSCs and
UC-MSCs (mean doubling time of 4 ± 1 days).
Umbilical Cord (UC)  Safe and non-invasive collection procedure.
 Abundant supply.
 UC-MSCs do not age over passages (i.e., senescence).
 Hypoimmunogenicity.
 Lower risk of graft-versus-host diseases (GvHD).
 Higher proliferation potential compared with BM and AT (mean
doubling time is 30 h).
 Higher expansion and engraftment capacity than BM-MSCs.
 UC-MSCs are less effective in inducing osteogenesis
compared to BM-MSCs.
J. Clin. Med. 2020, 9, 445 4 of 16
This work reviews the latest advances in MSC-based cell therapy in order to update the results
about the main MoA of MSCs as therapeutic agents for their clinical application. In particular, we
focus on three functions and mechanisms for applying this knowledge to get maximum repair and
regeneration of cell-derived therapeutics for regenerative medicine. Then, we focus on MSCs capacity
of migration, their paracrine effect, as well as MSC-mediated modifications on immune cell responses.
2. MSCs Mechanisms of Action
As MSCs perform their activity over the damaged tissue, it is necessary to know the potential
mechanisms that may be involved in their therapeutic action. In the last few years, several reports
have been published about the crucial MoA through which MSCs perform their role as keepers of
tissue homeostasis, as well as a tool for regenerative medicine.
Despite the evidence about MSCs direct differentiation and cell replacement, recent studies strongly
suggest that the most remarkable MoA of MSCs are attributed to their capacity of migration [17] and
paracrine effect [30,31], as well as the modifications that MSCs can cause over the immune system
(immunomodulation) [32,33].
2.1. Homing and Migration of MSCs
MSCs homing depends on their source of origin, that is, whether they are exogenous (injected) or
they simply act endogenously from one of its body reservoirs. MSCs can be exogenously administered
either locally or systemically. The local administration implies a non-vasculatory process where MSCs
are allocated at the target tissue [34].
On the other hand, the process of systemic MSC homing requires three phases:(i) direct
administration into blood vessels, (ii) extravasation at the lesion vicinity, and (iii) interstitial migration
toward the target site [23,34]. The extravasation and interstitial migration are commonly arranged to
the term “transendothelial migration” (Figure 1).
Independently of their origin, MSCs tend to enter into the vascular system in order to easily
reach the affected site. However, MSCs exhibit a remarkable tendency to get located in non-specific
tissues, such as the microvasculature and the capillary network, regardless of the presence or absence
of an specific injury and the multiple surface leukocyte-like receptors, which intervene in MSC
homing [23,35]. MSCs must approach the damaged site through the vascular system and then pass
through the endothelial wall in order to keep moving towards the lesion [17].
MSC extravasation is initiated by proinflammatory chemokines from the injury site, as tumor
necrosis factor-alpha (TNF-α) or histamine, which can activate endothelial cells of blood vessels, and
thus, induce P-selectin activation as well as vascular cell adhesion molecule 1 (VCAM-1) and the
expression of the intercellular adhesion molecule 1 (ICAM-1) on the endoluminal surface [36]. Then,
flowing MSCs begin to roll over the apical endothelial surface and the endothelium starts to upregulate
local ligands for extravasation as CD44 (homing cell adhesion molecule (HCAM)), CD49d, and very
late antigen 4 (VLA-4) [37]. When MSCs adhere to endothelium ligands, a signal expression pattern is
released ensuring a firm adhesion [23] (Figure 1). Extravasation involves, at first, the development of a
contact surface on the MSCs to be able to adhere to endothelial cells.
MSC tethering is dependent on the molecule adhesion pattern on its surface, which is formed by
galectin-1 and a huge variety of integrins, such as VLA-4. These molecules interact with P-selectin
and VCAM-1 in the endothelium surface, respectively. Besides, MSCs express platelet and neutrophil
derived molecules such as fibroblast growth factor receptors (FGFR), which interact with basic fibroblast
growth factor (bFBF) of endothelial cells and mediate in the adhesion of galectin-1 to P-selectin [23,38].
The molecular process starts with the recognition of proinflammatory cytokines, such as
interleukin-8 (IL-8), which activates phospholipase C (PLC), resulting in an increase at the inner
calcium (Ca2+) levels [23,39]. The rising levels of Ca2+ trigger a downstream signaling in which
guanine-exchange factors (GEF), GTPases (Rho and Rap1) and, tailin (an intracellular adapter protein)
are implied [23,40]. VLA-4 leads to a straightened position, on which the binding pocket is exposed and
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so conferring affinity to the integrin. Higher affinity can be achieved by a PLC-Rho/Rap1-independent
way, which involves phosphokinase C (PKC), phosphoinositide 3-kinase (PI3K)/Act, and other adapter
proteins such as integrin-linked kinase (ILK) [23].
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Figure 1. Homing and transendothelial migration of mesenchymal stromal cells (MSCs). MSCs can
act both endogenously or exogenously, performing a homing process, by which they move towards
the affected site following chemotactic signals in order to repair or contribute to the recovery of the
damaged tissue. bFBF: basic fibroblast growth factor; FGFR: fibroblast growth factor receptors; VLA-4:
very late antigen 4; VCAM-1: vascular cell adhesion molecule 1.
Once MSCs are attached to he endothelium, they form filopodia thanks to chemok ne ligand 9
(CXCL-9) stimulation [41], allowing MSCs to cross the intraluminal space by using proteases such as
metalloproteases. At the same time, MSCs get polarized developing a front po e by he action of an
intrac llular adaptor protein called FROUNT, which is linked to the C-C Chemokin Receptor type
2 (CCR2). When CCR2 starts to cluster, it results in a cytoskeletal reorganization, which cludes
enhanced actin polymerization [13]. Other C-C chemokine receptors (apart from CCR2) are expressed
by MSCs, such as CCR1, CCR4, CCR7, CCR9, CCR10, CXCR1, CXCR3, CXCR5, CXCR6, CX3CR1, and
CXCR4, which are thought to perform a r le in MSC homing. However, the predomin nt chemokines
in MSC homing r main unknown [42–44] (Figure 2).
MSCs overcome the endothelial basement membrane by the inter ction of different ext acellular
metalloproteases [45,46], which degrade the basal membrane type IV collagen [23,47]. When MSCs
have approached the dama ed site thr ugh the vascular system, the extravasate in order to keep
moving towards the l sion. MSC extravasation has been reported to be essential for MSCs in order to
perform their regenerative and restori g capacities ffectively [48]. The migration finishes once MSCs
have rea hed their target, where t y are expected to perform their ther peutic activity i order to
restore functionality [49].
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2.2. MSCs and Immune System
The response of MSCs after a stimulus is conditioned by the signals that these cells receive from
their surrounding microenvironment [50], such as inflammatory cytokines [51] or hypoxia factors [52].
After a stimulus, MSCs secrete immunoregulatory factors which eventually suppress or enhance the
immune response based on the physiological context [49,53].
The production of these factors by MSCs also relies upon their phenotype, which comes as a result
of the interaction between the paracrine factors from their surrounding microenvironment with the
receptors presented on MSCs surface, such as Toll-like receptors (TLR) [54]. According to Waterman et
al., two different MSC phenotypes can be distinguished: proinflammatory MSC phenotype (MSC1;
accomplished by TLR4 interaction with its ligand) and anti-inflammatory MSC phenotype (MSC2; as a
result of TLR3 bounding with its ligand) [50]. Both MSC1 and MSC2 are recognized to produce two
specific types of immunodulator factors, proinflammatory and anti-inflammatory factors (also known
as immunosuppressive factors), respectively [50] (Figure 3).
The status of pro-inflammatory or immunosuppressive is determined by the effects they can
cause over the immune cells. Thus, MSCs can ‘’immunomodulate” the activation and function of
several immune cells, both innate and adaptive cells, like T lymphocytes, macrophages, natural killer,
B lymphocytes, neutrophils, and dendritic cells [49]. MSCs are essential for T cell survival. In acute
inflammatory phases, effector T cells start to secrete a great number of proinflammatory cytokines
(IFN-γ, TNF, IL-1, and IL-17) which activates MSCs [30]. Then, MSCs start their immunomodulation
by releasing large amounts of prostaglandin E2 (PGE2), IL-10, Human Leukocyte Antigen-G (HLA-G),
indoleamine 2,3-dioxygen se (IDO), and chem kines, a CXCL9, CXCL10, and CXCL11 (ligands of
the T cell-specific chemokine receptor, XCR3 [30,55]. Likewise MSCs secre e CXCL12 (or str mal
cell-derived factor 1 alpha [SDF-1α]) nd CXCR4 [56]. hese chemokines attract T cells to the close
proxi ity of activated MSCs, where IDO is catabolized and its catabolites inhibit T cells, eventually
resulting in T cell poptosis.
Moreover, T cell proliferation and their differentiation into helper T cells, like Th1 and Th17, can
be inhibited by MSC secretome which includes HLA-G, galectins, and IDO among other molecules,
enabling macrophages to produce transforming growth factor-β (TGF-β) and promoting T regulatory
cells (Treg) differentiation [55,57,58]. Indeed, HLA-G can promote the apoptosis of both T and
B lymphocytes, impair the cytolysis of antigen-activated CD8+ cells, promote the activation of
CD4+CD25+ FoxP3+ regulatory T cells, and disturb the cytolysis, adhesion, and migration capacities
of natural killer (NK) cells. Therefore, HLA-G acts by decreasing the excessive immune response of
autoimmune disorders [55,59] (Figure 3).
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Other molecules produced by MSCs, known as galectins, are crucial in their immunosuppressive
effect. MSC-derived galectin-1 significantly disrupts the release of inflammatory cytokines, such as
TNFα, IFNγ, IL-2, and IL-10. Galectin-3 regulates the T cell proliferation, adhesion, and migration.
In addition, galectin-3 mediates in the reduction of stimulated T and B lymphocytes alongside
galectin-1 and galectin-9 [60,61].
Interestingly, the production of IDO is related to anti-inflammatory cytokine levels, as TGF-β,
which means that decreased levels of TGF-β match to diminished levels of IDO, desactivating MSCs
effect over immune cells and promoting immune response [62]. Therefore IDO is recognized as an
on–off switch system in immunomodulation, since it determines MSCs plasticity over T cells [57].
MSCs can also perform their immunomodulative action over other adaptative immune cells,
such as B cells. Activation of MSCs have been reported to inhibit B cell proliferation, plasm cell
differentiation, as well as IgE and IgG releasing from activated B cells by a direct cell–cell interaction,
while unstimulated MSCs do not suppress B cell proliferation and may even promote proliferation to
some extent [63,64] (Figure 3).
On the other hand, adipogenic-differentiated MSCs can promote the proliferation of activated
B cells by the secretion of the B cell activating factor (BAFF), while the opposite effect is observed in
MSCs [65] (Figure 3). Moreover, MSCs with secreted-IDO accelerates survival and proliferation of CD5+
B cells. These cells are considered a particular B cell subpopulation with a notable immunoregulation
ability performed by secreting IL-10 or inducing the differentiation of Tregs [66].
MSCs are not only associated with adaptative immune cells, but also with innate immune cells.
Concretely, activated NK cells can be recognized by MSCs, and consequently, MSCs are capable of
inhibiting NK cell proliferation by downregulating their activation via IL-2 or IL-15 [67]. Dendritic
cells (DC) are also affected by MSCs, thus MSCs inhibit CD14+ monocyte differentiation towards DC.
Besides MSCs block TNFα secretion by DC as promoting IL-10 and IL-4 secretion, which impedes
T cell differentiation into Th1 cells, directing these cells to differentiate into Treg and Th2 cells,
respectively [68].
Macrophages also interactact with MSCs. It has been reported that IDO high expression, as a result
of proinflammatory cytokines interaction, leads monocytes to differentiate into immunosuppressive
and anti-inflammatory type 2 macrophage phenotype (M2) [69]. Abumaree et al. revealed that
this MSC-dependent macrophage phenotype switching could occur from a proinflammatory type 1
macrophage phenotype (M1) to an anti-inflammatory type 2 phenotype (M2) in sepsis treatment [70].
Moreover, MSCs exhibit antimicrobial activity through the secretion of antimicrobial peptides
(AMPs), such as cathelicidin peptide LL-37, hepcidin, β-defensin 2, lipocalin 2, and Hepcidin [71,
72].These AMPs act in destroying bacterias by either altering the integrity of the microbial membrane
or by encouraging the release of proinflammatory cytokines which in turn favors the recruitment of
immune cells [71]. Therefore, there is an over-stimulation of the immune cells, as the formation of
neutrophil extracellular traps (NETs) by neutrophils [71].
Antimicrobial activity of MSCs can be considered counterproductive sometimes. Thus, MSCs
can support the host by immunosuppressing the environment by: (i) refrying the intensification of
pathological symptoms; (ii) helping to cure damaged tissue or organ; and (iii) allowing the formation of
an immune tolerant environment. However, excessive immune suppression can cause the completely
different effect, impeding the host from attacking the infection, and instead, favoring microbial effectors
to spread [72].
2.3. Paracrine Activity
Several studies have shown that only a small proportion of transplanted MSCs survives and
integrate into host tissues [48]. Therefore, the therapeutic effects of MSCs appear to not only depend on
direct cell-to-cell interaction. MSCs are also capable of providing beneficial effects such as cell survival
and proliferation, and to modulate the immune response through paracrine signaling. This paracrine
activity includes the secretion of small molecules as growth factors, cytokines, chemokines, and the
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release of EVs that contain a wide range of molecules such as mensenger RNA, peptides/proteins, and
microRNAs [73].
2.3.1. Secretome
Despite the fact that the homeostatic and immunomodulatory activity of MSCs were thought to
be reliant on MSC cell number, it has been seen that it depends more on the paracrine factors these cells
secrete, also known as ‘’secretome”, which is produced once MSCs are activated [49,53]. Therefore, in
response to environmental cues of the injury site, MSCs are activated and secrete various cytoprotective
paracrine factors to enhance regeneration of the damaged tissue [73].
Factors produced by MSCs include growth factors, such as hepatocyte growth factor (HGF), tumor
necrosis factor-inducible gene 6 protein (TSG6), vascular endothelial growth factor (VEGF), bFGF,
insulin-like growth factor 1 (IGF-1), chemokine (C-C motif) ligand 2 (CCL-2), epidermal growth factor
(EGF), platelet-derived growth factor (PDGF), as well as IL-6, TGF-β, prostaglandin E2, IDO, and
SDF-1 [4]. Together, these secreted factors may inhibit inflammatory responses, trigger angiogenic
process, promote endothelial and fibroblast activities, and facilitate the proliferation and differentiation
of progenitor cells into tissues in situ [49] (Figure 4).
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MSC activation remains essential in the production of all these factors. Inflammatory stimuli
and/or cross-talk with injured cells could enhanced the secretions and therapeutic effects of MSCs,
whereas non-activated MSCs do not induce a significant increase of paracrine factors which is necessary
for its therapeutic use [73]. Once MSCs are activated, the production of growth factors increases to
optimum levels when they can cause an efficient response. Chemokines are released by MSCs when
these cells have received any stimulus, starting the secretion of chemoattractant molecules [4].
When tissue is damaged, it suffers a fluctuant acute inflammation process. During the first phases
of the acute inflammation process, proinflammatory cytokines are highly expressed and contribute to
activating a larger number of MSCs leading to a better immunosuppressive response [74]. Multiple
J. Clin. Med. 2020, 9, 445 10 of 16
procedures have been considered to treat acute inflammation, among them, the administration of
proinflammatory cytokines before MSCs, or the usage of inhibitors of anti-inflammatory cytokines
previous to MSCs treatment [24].
In contrast to acute inflammation, in chronic inflammation, during remission or during
immunosuppressant treatments, the production of proinflammatory cytokines diminishes as the
concentration of anti-inflammatory cytokines, like TGF-β, increases. Besides, in this case, IDO
production is below the immunosuppressive threshold as well as chemokines, causing T lymphocytes
liberation so they can promote immune response [75,76].
In addition, immunosuppressant factors secreted by MSCs are not useful as coadjuvants
to conventional immunosuppressant drugs, despite having both quite similar effects; both
immunosuppressants and MSCs inhibit the inflammatory response by suppressing effector T cells.
In fact, it has been observed that the immunosuppressant effect of MSCs can be reverted by the
administration of immunosuppressant drugs as cyclosporine A and dexamethasone [77]. Not only can
in vivo endogenous factors affect MSC migration and homing, but also both are influenced by multiple
in vitro factors, concretely culture factors, such as age and passage number of the cells, the delivery
method, and culture conditions among others. For instance, the higher is the number of passages, the
less is the engraftment efficiency of MSCs [56].
Particularly, MSC attachment could be influenced by in vitro procedures, since the expression
pattern of α4 subunit of VLA-4 has been reported to differ depending on isolation and cultivation, but
also depending on individual donors and species [23].
2.3.2. MSC-Derived Extracellular Vesicles
In addition to secreted factors, the paracrine-protective mechanisms of MSCs include the
production of EVs, which include exosomes, and transfer of mitochondria [32,78,79]. Recently,
it has been shown that the EVs from MSCs contain vesicular cargo molecules that include messenger
RNA, transfer RNA, microRNA, and peptides/proteins. In addition, the EVs enclose lipids which are
able to mediate cell-to-cell communication and can exert therapeutic effects on various tissue injuries
via attenuation of immune cell activation [80,81] by ameliorating oxidative stress [82] or by decreasing
apoptosis [83] (Figure 5).
Therefore, exosomes are considered to play a major role in the communication between MSCs
and surrounding cells. For example, it has been shown that during in vitro culture with peripheral
blood mononuclear cells, MSC-derived exosomes extracted from bone marrow are able to suppress
the secretion of the pro-inflammatory factors TNF-α and IL-1β, while increase the concentration of
anti-inflammatory factor TGF-β [84].
Several studies indicated that exosomes could serve as a novel mechanism to transfer miRNAs
between cells to regulate gene expression offering therapeutic effects for liver [85], fibrosis [86],
stroke [87], and cardiovascular diseases [88,89]. Moreover, MSC-EVs therapeutic effects have also been
described for the adaptive and innate immune response [90]. A variety of studies have examined
the immunoregulatory function of MSC-EVs in autoimmune disease models such as autoimmune
murine models of type 1 diabetes, experimental autoimmune uveoretinitis, collagen-induced arthritis,
synovitis and multiple sclerosis [26]. In this sense, there is an increasing interest to use MSC-EVs in
human autoimmune diseases as an alternative to cell therapy.
Regarding the transfer of mitochondria from MSCs EVs, it was demonstrated that there is an
increase of phagocytic activity after mitochondrial transfer from MSC to innate immune cells [79].
For example, the treatment of murine alveolar macrophages with MSC-derived EVs reduce lung
injury due to MSCs induce a highly phagocytic and antiinflammatory macrophage phenotype through
EV-mediated mitochondrial transfer [91].
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Figure 5. Mesenchymal stromal cell-secreted exosomes perform a role in cell-to-cell communication, as
well as triggering therapeutic effects, by a reduction of oxidative stress, increasing cell live expectancy,
and exhibiting an immunological tolerance through the reduction of activation and proliferation of
adaptative immune cells and the differentiation of innate cells towards regulatory phenotypes.
Due to MSC-EVs are surrounded by a phospholipid bilayer, they are more stable when freezing
and thawing than MSCs, therefore easily prebanked. In addition, EVs present many advantages,
including low immunogenicity, lack endogenous tumor-formation potential, in vivo stability, and
high delivery efficiency. However, the dose of injected EVs and the route of administration affected
their biodistribution pattern [90]. Further studies to better understand the mechanisms underlying
MSC-EVs functions are necessary for future EVs-based therapy in the clinic.
3. Conclusions
MSC-based cell therapy involves the administration of MSCs as a medicinal product. These cells
are characterized by their differentiation potential, migration capacity, immune system modulation,
and paracrine activity which can be used as a therapeutic agent in human treatments.
MSC therapy has been investigated extensively in clinical research to evaluate its therapeutic
effect in degenerative, immunological, or inflammatory diseases lacking appropriate treatments.
First stage results of clinical research have proven safety and tolerability, however, future directions
in hMSCs(human MSCs) will involve elucidation of molecular mechanisms by which different
microenvironmental cues influence stem cell behavior, followed by translation of these findings to
their clinical applications. Paracrine potency and therapeutic efficacy obtained from MSCs are known
to vary with source and batch. For successful clinical translation, optimized protocols for MSCs
isolation and ex vivo preparation will be necessary. It has been concluded that transplanted MSCs exert
their therapeutic effects by acting as “paracrine factor factories” that possess immunomodulation and
immune-privileged properties. The high paracrine ability includes EVs release. The use of a cell free
preparation comprising of MSC-derived EVs as a conditioning media make these cells an important
material for the development of new approaches for non-cell-based therapies. However, there are
still new parameters to address in order to determinate a preconditioning treatment to enhance the
paracrine potency of MSCs, such as exogenous factors that may help to greatly impact on the MSCs
biological properties and eventually on their therapeutic abilities.
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